- Conditions
- Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Interventions
- Olaparib, Physician's choice chemotherapy
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 42
- States / cities
- San Diego, California • Santa Rosa, California • Whittier, California + 35 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2065–2088
of 7,464
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Trilaciclib, Sacituzumab Govitecan-hziy
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 22
- States / cities
- Chandler, Arizona • Bakersfield, California • Los Angeles, California + 18 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- AC2993
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 219
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, intensity-modulated radiation therapy
- Biological · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 250
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Auburn, California + 191 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- 75 mg LX4211, 200 mg LX4211, 400 mg LX4211, Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 56
- States / cities
- Anaheim, California • Carmichael, California • Greenbrae, California + 48 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Belumosudil (KD025)
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 30 more
- Conditions
- Opioid-induced Bowel Dysfunction
- Interventions
- Lubiprostone, Placebo
- Drug
- Lead sponsor
- Sucampo Pharma Americas, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 115
- States / cities
- Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more
- Conditions
- Suicide Risk | Patient
- Interventions
- SAFE VET
- Behavioral
- Lead sponsor
- VA Eastern Colorado Health Care System
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 8
- States / cities
- Long Beach, California • San Diego, California • Denver, Colorado + 5 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 14
- States / cities
- Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 11 more
- Conditions
- Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Interventions
- Standard Treatment, AGS-003
- Drug · Biological
- Lead sponsor
- Argos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 88
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more
- Conditions
- Rib Fracture Multiple
- Interventions
- Operative
- Device
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Bladder Cancer
- Interventions
- gemcitabine hydrochloride, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 70
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 44 more
- Conditions
- Obesity, Heart Failure
- Interventions
- NNC0487-0111, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 206
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more
- Conditions
- Radiculopathy, Myelopathy
- Interventions
- Anterior Cervical Discectomy and Fusion (ACDF), PCM Cervical Disc
- Device
- Lead sponsor
- NuVasive
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 494 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 23
- States / cities
- Beverly Hills, California • Greenwood Village, Colorado • Washington D.C., District of Columbia + 18 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Omnipod Horizon™ Automated Glucose Control System
- Device
- Lead sponsor
- Insulet Corporation
- Industry
- Eligibility
- 6 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Denver, Colorado • Atlanta, Georgia + 3 more
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 179
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Behavioral Dietary Intervention, Compliance Monitoring, Counseling, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,070 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 687
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- CAM2029, Octreotide LAR, Lanreotide ATG
- Drug
- Lead sponsor
- Camurus AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Amrubicin, Topotecan
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
- Conditions
- Major Depressive Disorder
- Interventions
- Cariprazine, Placebo, Antidepressant Therapy (ADT)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,022 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 83
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
- Conditions
- Lung Cancer
- Interventions
- cetuximab, docetaxel, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 77
- States / cities
- Anchorage, Alaska • Los Angeles, California • Marysville, California + 55 more
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Cisplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium, Questionnaire Administration, Vinorelbine Tartrate
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 1139
- States / cities
- Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 712 more
- Conditions
- Pulmonary Tuberculosis
- Interventions
- rifapentine, rifapentine 10 mg/kg, rifapentine 15 mg/kg, rifapentine 20 mg/kg
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis
- Interventions
- Balsalazide Disodium
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Fayetteville, Arkansas + 82 more